Skip Navigation



Carcinogenesis Advance Access published online on September 3, 2007

Carcinogenesis, doi:10.1093/carcin/bgm197
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
28/12/2501    most recent
bgm197v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Nambiar, S.
Right arrow Articles by Hengge, U. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nambiar, S.
Right arrow Articles by Hengge, U. R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance

Sandeep Nambiar1, Alireza Mirmohammadsadegh1, Mohamed Hassan1, Rodrigo Mota1, Alessandra Marini1, Amine Alaoui1, Andrea Tannapfel2, Johannes H. Hegemann3 and Ulrich R. Hengge1

1 Department of Dermatology Heinrich-Heine-University Duesseldorf, Germany
2 Institute of Pathology, Ruhr-University, Bochum, Germany
3 Institute of Functional Genomics for Microorganisms, Heinrich-Heine-University Duesseldorf, Germany

Corresponding author: Prof. Dr. Ulrich R. Hengge, Department of Dermatology, Heinrich-Heine-University, Moorenstrasse 5, D-40225 Duesseldorf, Germany. Phone: 49-211-811-8066; Fax: 49-211-811-8830; E-mail: ulrich.hengge{at}uni-duesseldorf.de

Malignant melanoma is one of the most aggressive and invasive metastatic tumors derived from melanocytes that have undergone malignant transformation by acquisition of genetic and epigenetic alterations. Oligonucleotide microarray-based screening of distinct stages in the tumor progression model of cutaneous melanoma identified ASK/Dbf4, as a novel determinant for melanoma development. qReal-time-PCR based confirmation of ASK/Dbf4 on a series of benign nevi, dysplastic nevi, primary cutaneous melanomas, and cutaneous melanoma metastases and a number of other controls using normal human melanocytes (NHM) as calibrator not only revealed a melanoma-specific overexpression but also revealed that higher ASK/Dbf4 expressing melanomas were associated with lower relapse-free survival. Additionally, we also confirmed the observed overexpression of ASK/Dbf4 in melanoma using Western blot analysis and immunohistochemistry. As ASK/Dbf4 is known to be a cyclin-like regulatory subunit of mammalian Cdc7 from studies in yeast, the present study investigated its role in melanoma cells. In keeping with its expected role, our data suggest that upregulated ASK/Dbf4 is localized in the nucleus and binds to human Cdc7 to form Cdc7-ASK/Dbf4 complexes in several analyzed melanoma cell lines. Further, we demonstrate that siRNA-mediated depletion of ASK/Dbf4 retarded melanoma cell survival and proliferation. In summary, we report the differential regulation of a novel gene, namely ASK/Dbf4, in melanoma and suggest that upregulation of ASK/Dbf4 is a novel molecular determinant with prognostic relevance that confers a proliferative advantage in cutaneous melanoma.

Key Words: ASK/Dbf4 • gene expression • cutaneous melanoma • oligonucleotide microarray • Cdc7 • prognosis

Received July 17, 2007; revised August 21, 2007; accepted August 21, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.